Amphastar Pharmaceuticals Full Year 2024 Earnings: Eps Misses Expectations
Amphastar Pharmaceuticals' full-year 2024 earnings per share (EPS) missed analyst estimates by 7.4%, despite revenue growth of 14% from the previous year. The company's net income rose 16% to US$159.5m, with a profit margin of 22%. Amphastar's shares have declined 9.1% from a week ago.
- This mixed performance suggests that Amphastar's cost structure and pricing power may be subject to intense scrutiny by investors, who may demand higher returns for the risks associated with the company's business.
- What implications will this miss have on Amphastar's ability to attract new investors or retain existing ones, particularly in a highly competitive pharmaceuticals industry?